Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Mylan Seeks To Overturn FDA's Provigil Decision

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/05/2012 | 07:10pm CEST

Mylan Inc. (>> Mylan Inc.) said it is seeking to overturn a decision by the U.S. Food and Drug Administration that awarded Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) exclusivity for its generic version of Cephalon Inc.'s wakefulness drug Provigil.

The generic drug maker said Thursday it has filed a lawsuit against the FDA in the U.S. district court for the District of Columbia. Mylan is seeking an immediate court order entitling it to exclusivity as well as immediate approval for its abbreviated new drug application.

Mylan alleges Teva did not maintain valid certifications as a result of its acquisition last year of Cephalon and thus is not entitled to exclusivity based on patent certifications. Mylan also alleges that the FDA should have found Mylan as the sole first filer on one of the patents for Provigil.

Earlier Thursday, Teva said the FDA has decided that Teva is the sole first-to-file for both of Provigil's patents, which entitled the company to 180-day exclusivity. The FDA decided that Cephalon's launch of generic Provigil on March 29 triggered the exclusivity.

In October, the Federal Trade Commission required Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant in connection with Teva's acquisition of Cephalon. The FTC agreement also required Teva to enter a supply agreement that allows a competing firm, Par Pharmaceuticals Inc. (PRX), to sell a generic version of Provigil in 2012.

Teva expects Par Pharmaceuticals to launch a second generic product on April 6.

Mylan shares slipped 1.8% to $22.74 in recent trading. The stock is up 5.9% so far this year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Mylan Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN INC
03:51p Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
07/21 MYLAN NV : Publishes Supplement to Meda Offer Document
07/21 MYLAN NV : and Biocon Announce Regulatory Submission for Proposed Biosimilar Peg..
07/20DJMYLAN NV : EU Approves Mylan's $7.2 Billion Acquisition of Meda
07/20 MYLAN NV : Launches Generic Crestor® Tablets
07/20 MEDA : Mylan gets EU approval for Meda purchase, subject to conditions
07/20DJAbbott Labs Profit Tops Views
07/15 EXCLUSIVE - MYLAN TO GET EU GREEN LI : sources
07/11 MYLAN NV : Launches Generic Temodar® Capsules
07/07 MYLAN NV : to Report Second Quarter 2016 Financial Results on August 9, 2016
More news
Sector news : Pharmaceuticals - NEC
03:51p Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
01:45pDJEli Lilly Revenue Rise Helped by New Products
01:40pDJELI LILLY : Revenue Helped by Sales of New Drugs
09:25a Takeda sets bidding deadline for chemical firm stake, CVC and Carlyle may bid..
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Financials ($)
Sales 2016 10 902 M
EBIT 2016 3 288 M
Net income 2016 2 070 M
Debt 2016 10 187 M
Yield 2016 -
P/E ratio 2016 13,10
P/E ratio 2017 10,14
EV / Sales 2016 3,14x
EV / Sales 2017 2,57x
Capitalization 24 036 M
More Financials
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 58,1 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%24 036
JOHNSON & JOHNSON21.58%343 528
PFIZER INC.13.94%223 065
NOVARTIS AG-5.13%218 815
ROCHE HOLDING LTD.-9.62%217 668
MERCK & CO., INC.10.87%162 096
More Results